

Racial/Ethnic and Gender Disparities in Renal Cell Carcinoma Incidence and Survival

Helen Shi Stafford,* Sidney L. Saltzstein, Suzuho Shimasaki, Catherine Sanders, Tracy M. Downs and Georgia Robins Sadler

From the Rebecca and John Moores UCSD Cancer Center (HSS, SLS, SS, CS, TMD, GRS), University of California, San Diego Medical Center, Department of Surgery/Division of Urology (TMD) and Department of Surgery/Division of General Surgery (GRS), University of California, San Diego School of Medicine (HSS, SLS), La Jolla, University of California, Los Angeles School of Public Health, Los Angeles (SS), Department of Surgery/Urology Section, Veterans Affairs San Diego Healthcare System (TMD), San Diego, California, and Ohio State University College of Medicine, Columbus, Ohio (CS)

Purpose: We used a population based cancer registry to examine trends in renal cell carcinoma incidence and survival among 4 racial/ethnic groups (white, black, Hispanic and Asian/Pacific Islander) and both genders.

Materials and Methods: Race/ethnicity, gender, age, staging, length of survival and cause of death data were analyzed using 39,434 cases of renal cell carcinoma from 1988 to 2004 from the California Cancer Registry. Annual age adjusted incidence rates and relative survival rates were calculated for the racial/ethnic and gender groups. These rates and the percent of localized cancer were plotted by year, and Microsoft Excel® was used to calculate linear regression equations. Median age was also calculated. Z-tests and chi-square tests were performed to determine p values.

Results: An increase in renal cell carcinoma incidence was found with localized cancer accounting for most of the increase. Black patients had a significantly higher incidence rate ($p < 0.0001$) and lower survival rate ($p < 0.0001$) than all other races/ethnicities despite having more localized cancer ($p < 0.005$). Black patients were also diagnosed at a younger age ($p < 0.0001$) than their counterparts. On the other hand Asian/Pacific Islanders had a lower incidence rate ($p < 0.0001$) and higher survival rate ($p < 0.05$) than all other races/ethnicities. Males had approximately twice the incidence rate of females and a lower survival rate ($p < 0.005$).

Conclusions: Higher incidence rates and lower survival rates were identified among black and male patients compared to their counterparts, while Asian/Pacific Islanders showed the opposite trends. Such racial/ethnic and gender disparities in renal cell carcinoma incidence and survival may help elucidate biological, behavioral and environmental factors that can potentially be addressed.

Key Words: kidney neoplasms, continental population groups, sex, incidence, survival rate

Renal cancer was estimated to be responsible for approximately 51,190 new cancer cases in the United States in 2007, making it the 7th most common cancer among men. It was also estimated to have caused 12,890

Submitted for publication August 31, 2007.

Supported by National Cancer Institute Grant R25CA65745, Cancer Center Core Grant #5 P30 CA023100-22, UCSF/UCLA Minority Training Program for Cancer Control Research Grant R25 CA078583, National Institutes of Health Division of National Center on Minority Health and Health Disparities EXPORT Grant P60MD00220, the Minority Institution/Cancer Center Partnership Program Grants #U56 CA92079 and #U56 CA92081, and the National Institute of Aging Medical Student Training in Aging Research Grant T35AG026757.

The collection of cancer incidence data used in this study was supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by the California Health and Safety Code Section 103885, the National Cancer Institute's Surveillance, Epidemiology and End Results Program, and the Centers for Disease Control and Prevention National Program of Cancer Registries. The ideas and opinions expressed herein are those of the author, and endorsement by the State of California, Department of Health Services, the National Cancer Institute and the Centers for Disease Control and Prevention is not intended nor should be inferred.

* Correspondence: UCSD School of Medicine, Moores UCSD Cancer Center, 3855 Health Sciences Drive MC 0850, La Jolla, California 92093-0850 (telephone: 858-822-7611; FAX: 858-534-7628; e-mail: heshi@ucsd.edu).

See Editorial on page 1657.

For another article on a related topic see pages 2010 and 2057.

deaths.¹ Of these renal cancers renal cell carcinoma (also called renal cell adenocarcinoma, clear cell cancer of the kidney, hypernephroma, and Grawitz tumor) accounted for 85%, while renal pelvis cancer accounted for most of the remainder.² Renal cell carcinoma and renal pelvis cancer have been shown to have distinct epidemiology, histology, therapy and natural history.³ We focused exclusively on RCC because it is the predominant form of renal cancer and occurs in sufficient numbers to permit in-depth analysis.

RCC is twice as common in men than in women,⁴ with the average age at diagnosis in the early 60s.⁵ Studies have shown that having a first degree relative with any kidney cancer is associated with a 2 to 3-fold increased risk.⁶ Smoking, hypertension and obesity have also been strongly associated with RCC.^{5,7} The only consistently reported dietary risk factor has been a lack of fruit and vegetable consumption.⁵

Recent epidemiological studies have suggested that the incidence rate of RCC is increasing predominantly accounted for by localized cancer.^{5,8-12} Data from the National Cancer Institute's SEER program showed that the incidence rate of RCC has increased more rapidly in black than white patients and in females than males.^{5,8,9} Differences between the survival rates of black and white patients were also found, but the results were confounded by factors such as socioeconomic disparities, performance status and comorbid conditions.⁸

TABLE 1. Number of patients by race/ethnicity and gender

	No. Male	No. Female	Totals
White	17,652	9,652	27,304
Black	1,738	1,024	2,762
Hispanic	4,263	2,892	7,155
Asian/Pacific Islander	1,282	702	1,984
Other/unknown	146	83	229
Totals	25,081	14,353	39,434

This study attempts to confirm recent reports of disparities in incidence and survival between black and nonHispanic white patients with RCC using data from the CCR from 1988 to 2004. Additionally, the diverse demographics of California allow Hispanic and A/PI populations to be included in the study in sufficient numbers for analysis. Incidence and survival data were also analyzed by gender for each of the racial/ethnic groups and the overall patient population.

MATERIALS AND METHODS

Database

The data used for this project came from the California Cancer Registry, which has been the repository for all incident cancer cases in the state of California since 1988. A major benefit of using the CCR is its consistent population base. Previous studies have used SEER program data between 1975 and 2002. During this period the data coverage expanded from 9 to 11 to 13 regions.^{5,8,9} Two of the added regions were Los Angeles County and San Jose-Monterey, California, which may have greatly altered the racial/ethnic distribution. On the other hand, this study used a database which contains state-mandated reports of all cancer cases in California since 1988.

New cancer cases are reported to the CCR by physicians, health facilities, laboratories, nursing homes, autopsies and death certificates. There are penalties for the failure to report new cases. Cases are abstracted by Certified Cancer Abstractors. Ten regional cancer registries serve as receiving facilities and report to the central registry. Tasks such as quality assurance and the removal of duplicate entries are completed at the regional and central levels. The CCR is certified by the North American Association of Central Cancer Registries, and now the entire state is part of the SEER program. Thus, the CCR uses the same histological codes as does the SEER program. Currently, complete data are available from 1988 to 2004.

Statistical Methods

All patients diagnosed with RCC (ie cancers originating from the kidney, excluding those of the renal pelvis) were chosen from the database. The variables selected for further analysis were race/ethnicity (white, black, Hispanic or A/PI), gender, stage at time of diagnosis (localized, regional, or distant), age at diagnosis, length of survival after diagnosis and cause of death.

Annual age-adjusted incidence rates and relative survival rates for the first 10 years following diagnosis were analyzed using standard statistical analytical tools.¹³ Annual incidence rates, survival rates and percent of localized

cancer were plotted by year, and Microsoft Excel® was used to calculate linear regression equations. Median age at diagnosis was also calculated. Z-tests and chi-square tests were used to determine p values.

Analysis for each variable was conducted after excluding the cases in which the variable was categorized as unknown. Gender was known for all cases, and the percentage of unknown data was 0.0% (7/39,434) for age, 0.6% (227/39,434) for race/ethnicity and 5.2% (2,062/39,434) for stage.

RESULTS

Incidence Trends

From 1988 to 2004 a total of 39,434 cases of RCC were reported to the CCR. Table 1 lists these cases by race/ethnicity and gender. Annual AAIRs were computed for the total population, and the gender and racial/ethnic groups. The AAIRs were plotted for each year, and linear regression equations were calculated to determine the slope (figs. 1 and 2).

For the total population the slope of the linear regression equation was 0.15. On average, male incidence rates were about twice that of females (fig. 1). The slopes in figure 1 show that the incidence rate of males also increased at approximately twice the rate of females. As shown in figure 2 incidence rates for blacks vs all other races/ethnicities were found to be significantly higher ($z = 9.02, p < 0.0001$) and to have increased more rapidly with a slope of 0.21. This was also true for Hispanics, although to a slightly lesser extent ($z = 11.31, p < 0.0001$, slope of 0.20). Incidence rates were found to be significantly lower in A/PIs than in the total population ($z = 4.67, p < 0.0001$). Whites showed a slightly higher incidence rate than the total population ($z = 3.92, p < 0.001$), although the statistical significance is most likely due to the large sample size.

The percent of RCC cases found to be localized at diagnosis increased steadily from 1988 to 2004 with a slope of 0.93 (fig. 3). Percent localized cancer was also plotted for the 2 genders. Overall, females showed a significantly higher percent of localized cancer than males (chi-square 59.7, $p < 0.0001$). Males had a greater rate of increase of percent localized cancer (slope 0.98) than females (slope 0.93). When the individual racial/ethnic groups were explored, tremendous year-to-year variation within the groups made graphing unproductive. However, table 2 lists the overall percent




FIG. 1. Age adjusted incidence rate of RCC from 1988 to 2004 by gender.




FIG. 2. Age adjusted incidence rate of RCC from 1988 to 2004 by race/ethnicity

of localized, regional and distant cancer for each racial/ethnic and gender group. Localized and regional cancer varied between the groups whereas distant cancer was relatively constant. Black patients had a significantly higher percent of localized cancer compared to all other patients (chi-square 19.3, $p < 0.005$). On the other hand, white patients had a statistically significantly lower percent of localized cancer compared to all other patients (chi-square 6.08, $p < 0.025$).

The median age at diagnosis by race/ethnicity and gender is shown in table 3. Significant differences in age at diagnosis were found between males and females ($z = 8.92$, $p < 0.0001$). Black and Hispanic patients had the same median age at diagnosis of 61 years, which was significantly lower than their respective counterparts ($z = 11.4$, $p < 0.0001$ and $z = 22.8$, $p < 0.0001$, respectively). A/PIs also had a significantly lower median age at diagnosis of 63 years vs their counterparts ($z = 4.67$, $p < 0.0001$). White patients had a higher median age at diagnosis of 66 years compared to all other races/ethnicities ($z = 28.6$, $p < 0.0001$).

Survival Analysis

Relative survival rates for the first 10 years after diagnosis are shown in figure 4 for the racial/ethnic groups. Relative survival rates were higher for A/PIs ($z = 1.96$, $p = 0.05$) and significantly lower for black patients ($z = 6.43$, $p < 0.0001$)




FIG. 3. Percent local stage RCC from 1988 to 2004

	% Local	% Regional	% Distant
White	58.2	20.1	21.7
Black	63.1	15.5	21.4
Hispanic	57.4	20.9	21.7
Asian/Pacific Islander	60.3	18.1	21.6
Male	56.8	20.8	22.4
Female	61.5	18.1	20.4
Total study population	58.5	19.8	21.7

compared to their counterparts. Relative survival rates were also significantly higher for females than for males ($z = 3.06$, $p < 0.005$).

Relative survival rates for patients with localized RCC by racial/ethnic group are shown in figure 5. Comparing only localized RCC augmented the difference in survival between black patients and all other groups.

Table 4 shows the causes of death for the study population divided into racial/ethnic and gender groups. Cause of death is listed as neoplasm specific for approximately a third of RCC deaths, and of those neoplasm deaths approximately 80% were listed as kidney specific. Approximately 10% of patients who died did not have a death certificate available to establish the cause of death. White patients had a significantly higher percentage of neoplasm as the cause of death compared to the other races/ethnicities, while Hispanics and A/PIs had fewer death certificates available.

DISCUSSION

The current analysis shows that annual age adjusted incidence rates of RCC among Californians have increased steadily between 1988 and 2004. As shown in previous studies, localized cancer accounted for most of the increased incidence.^{8,9} This may largely be due to the increased incidental detection of RCC, resulting from the growing use of ultrasound and CT for nonrenal cancer related problems.¹⁰⁻¹² Risk factors such as smoking, hypertension, obesity and diet have been associated with RCC,^{5,7} and may have a role in the increasing incidence. Of these factors smoking prevalence has decreased over time and, therefore, may not explain the increasing incidence of RCC. However, the prevalence of obesity has increased significantly over time and could be contributing to the increased incidence.

Black patients were found to have a significantly higher incidence rate than all other races/ethnicities. They were also diagnosed at a younger age with more localized (low stage) cancer. It would be unlikely for this higher incidence rate to be explained by increased incidental detection since black patients tend to have less access to health care for undergoing ultrasound and CT.¹⁴ It is possible that the disparity in incidence rates may be due in part to racially based genetic and biological differences in the tumor and the

	Male	Female	Combined	Standard Error
White	65	68	66	0.078
Black	60	62	61	0.247
Hispanic	61	62	61	0.158
Asian/Pacific Islander	63	64	63	0.298
Total study population	64	66	65	0.066




FIG. 4. RCC relative cumulative actuarial survival from 1988 to 2004 by race/ethnicity.

patient. Black patients also have a much higher prevalence of hypertension at a younger age,¹⁵ which is a significant risk factor for developing RCC. Overall greater environmental stress experienced by the black community may also contribute to increased incidence of RCC.

Despite having more localized cancer black patients with RCC still have a significantly lower survival rate than all other races/ethnicities. This decrease in survival is augmented when comparing only localized RCC. Previous studies have also shown this disparity, while acknowledging confounding factors such as comorbidities.⁸ Other studies have attempted to account for comorbidities by analyzing death certificate cause of death data to isolate cancer specific deaths.⁵ However, death certificate accuracy is often as low as 40% due to wording inaccuracies and lack of training among physicians.¹⁶ Because of this and because 10% of the patients in this study did not even have a death certificate available, it was decided that the cause of death data were not an effective means for accounting for comorbidities.

Instead, relative survival data were used to account for other causes of death that would be present in the general population for each gender and age. Relative survival rates confirmed that black patients do not survive as well as their nonblack counterparts. This is true although black patients are diagnosed with more localized cancer. It was also noted that black patients are diagnosed at a younger age, a circumstance that should give them more resilience in the face of aggressive treatments, but may




FIG. 5. Localized RCC relative cumulative actuarial survival from 1988 to 2004 by race/ethnicity.

	% Neoplasm (% kidney specific)	% Other	% Death Certificate Not Available
White	36.0 (79.1)	54.7	9.3
Black	32.0 (80.0)	59.6	8.4
Hispanic	31.9 (84.9)	57.0	11.1
Asian/Pacific Islander	31.9 (81.8)	54.6	13.5
Male	34.8 (79.7)	55.5	9.8
Female	35.1 (80.8)	55.3	9.6
Total study population	34.8 (80.1)	55.5	9.7

suggest the presence of a more aggressive cancer. This observed disparity in survival rates for black patients may also be due in part to lack of access to treatment and additional stressors associated with lower socioeconomic status. Moreover, Berndt et al showed that the difference in survival between black and white patients with RCC can be substantially reduced by accounting for comorbidities and the lower likelihood of receiving nephrectomy treatment among black patients.¹⁷

On the other hand, A/Pis were found to have a significantly lower annual age-adjusted incidence rate and a higher relative survival. This is consistent with trends in overall cancer incidence and survival among A/Pis in California reported in 2003.¹⁸ This may partly be due to the higher percentage of localized cancers diagnosed among A/Pis. Other factors could include differences in tumor aggressiveness, comorbid diseases, cultural behaviors, and access to and use of the health care system. However, it is important to note that different Asian ethnic subgroups often have different cancer burdens, which may skew the overall trends in the A/PI population.¹⁹

As previously reported, males were found to have approximately twice the incidence rate of females.⁴ However, contrary to previous reports, male incidence rates appeared to increase more rapidly than female incidence rates.^{5,9,20} This new trend may be related to increasing localized cancer incidence, since localized cancer was also shown to have increased more rapidly among males than females. Additionally, males were found to have a lower relative survival rate than females. This may be a result of the higher percent of localized cancer among females. A 2002 study suggested that the difference between male and female survival rates may be due to more extensive use of the health care system by females than males.²⁰ Other potential causes of this observed disparity include biological differences in the tumor and in male vs female patients, as well as the higher prevalence of hypertension in males vs females.¹⁶

As with most studies the findings of this study must be generalized with caution. Gaps in data completeness for staging and, to a much lesser extent, race/ethnicity may affect accuracy. Additionally, comorbidity data are not available in the CCR, which could influence the disparities in survival.

CONCLUSIONS

The incidence of RCC in California has increased steadily between 1988 and 2004, with localized cancer accounting for most of that increase. Significant differences in incidence rates and survival rates were observed among racial/ethnic

and gender groups. Black patients had a significantly higher incidence rate and lower relative survival rate than all other races/ethnicities, while Asians/Pacific Islanders showed just the opposite. Males had twice the incidence rate and a slightly lower relative survival rate than females. Identification of such racial/ethnic and gender disparities in RCC incidence rates and survival rates may help elucidate biological, behavioral, and environmental factors that can potentially be addressed.

Abbreviations and Acronyms

AAIRs	=	annual age adjusted incidence rates
A/PI	=	Asian/Pacific Islander
CCR	=	California Cancer Registry
CT	=	computerized tomography
RCC	=	renal cell carcinoma
SEER	=	Surveillance, Epidemiology, and End Results Program

REFERENCES

1. American Cancer Society: Cancer Facts & Figures 2007. Atlanta: American Cancer Society 2007.
2. SEER Program Public Use Data Tapes 1973–2002, November 2004 Submission. Bethesda: National Cancer Institute, Division of Cancer Control and Population Science, Surveillance Research Program, Cancer Statistics Branch 2005.
3. Mufti GR, Gove JR, Badenoch DF, Fowler CG, Tiptaft RC, England HR et al: Transitional cell carcinoma of the renal pelvis and ureter. *Br J Urol* 1989; **63**: 135.
4. Cancer incidence in five continents. Volume VIII. IARC Sci Publ 2002; 1.
5. Lipworth L, Tarone RE and McLaughlin JK: The epidemiology of renal cell carcinoma. *J Urol* 2006; **176**: 2353.
6. Noordzij MA and Mickisch GH: The genetic make-up of renal cell tumors. *Urol Res* 2004; **32**: 251.
7. Amling CL: The association between obesity and the progression of prostate and renal cell carcinoma. *Urol Oncol* 2004; **22**: 478.
8. Vaishampayan UN, Do H, Hussain M and Schwartz K: Racial disparity in incidence patterns and outcome of kidney cancer. *Urology* 2003; **62**: 1012.
9. Chow WH, Devesa SS, Warren JL and Fraumeni JF: Rising incidence of renal cell cancer in the United States. *JAMA* 1999; **281**: 1628.
10. Bretheau D, Lechevallier E, Eghazarian C, Grisoni V and Coulange C: Prognostic significance of incidental renal cell carcinoma. *Eur Urol* 1995; **27**: 319.
11. Homma Y, Kawabe K, Kitamura T, Nishimura Y, Shinohara M, Kondo Y et al: Increased incidental detection and reduced mortality in renal cancer—recent retrospective analysis at eight institutions. *Int J Urol* 1995; **2**: 77.
12. Jayson M and Sanders H: Increased incidence of serendipitously discovered renal cell carcinoma. *Urology* 1998; **51**: 203.
13. Epi Info 6.01. Atlanta: Center for Disease Control and Prevention 1994.
14. Geronimus AT, Bound J, Waidmann TA, Hillemeier MM and Burns PB: Excess mortality among blacks and whites in the United States. *N Engl J Med* 1996; **335**: 1552.
15. Vargas CM, Ingram DD and Gillum RF: Incidence of hypertension and educational attainment: the NHANES I epidemiologic followup study. First National Health and Nutrition Examination Survey. *Am J Epidemiol* 2000; **152**: 272.
16. Lakkireddy DR, Basarakodu KR, Vacek JL, Kondur AK, Ramachandruni SK, Esterbrooks DJ et al: Improving death certificate completion: a trial of two training interventions. *J Gen Intern Med* 2007; **22**: 544.
17. Berndt SI, Carter HB, Schoenberg MP and Newschaffer CJ: Disparities in treatment and outcome for renal cell cancer among older black and white patients. *J Clin Urol* 2007; **25**: 24.
18. Nasser K: Secular trends in cancer mortality, California 1970–1998. *Cancer Detect Prev* 2004; **28**: 143.
19. McCracken M, Olsen M, Chen MS Jr, Jemal A, Thun M, Cokkinides V et al: Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. *CA Cancer J Clin* 2007; **57**: 190.
20. Beisland C, Medby PC and Beisland HO: Renal cell carcinoma: gender difference in incidental detection and cancer-specific survival. *Scand J Urol Nephrol* 2002; **36**: 414.